Navigation Links
Clarient to Commercialize Novel Breast Cancer Profile
Date:1/9/2008

Clarient Insight(TM) Dx Breast Cancer Profile Represents First Molecular

Test Applicable to All Stages of Operable Breast Cancer

ALISO VIEJO, Calif., Jan. 9 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it will commercialize a novel breast cancer test, the first molecular test available that is applicable to all stages of operable breast cancer, including lymph node-positive patients. The new offering, called Clarient Insight(TM) Dx Breast Cancer Profile, will be sold by Clarient through an exclusive license agreement with Prediction Sciences, a La Jolla, CA-based company that develops high-value molecular diagnostics for disease detection, prognosis and selection of appropriate therapy.

Clarient's Insight Dx Breast Cancer Profile is a series of molecular assays that, when combined using Prediction Sciences' proprietary algorithm, offer information designed to help individual patients and their physicians understand the risk of recurrence and assist them in selecting the most appropriate therapy. The profile could allow patients to avoid the toxic effects of unnecessary chemotherapy, thereby reducing the overall cost of care. The availability of the test through Clarient reflects the healthcare industry's move toward personalized medicine that helps physicians understand the unique aspects of a patient's disease in order to develop more effective treatment plans. Leading oncology organizations have recommended adopting this type of test since a large percentage of women who undergo chemotherapy have little chance of benefiting from the toxic treatment. According to industry analy
'/>"/>

SOURCE Clarient
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
3. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
4. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
5. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
6. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
7. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
8. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
9. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
10. First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
11. DOE JGI plumbs termite guts to yield novel enzymes for better biofuel production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 18, 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ... manufacturing and marketing of innovative therapies for autoimmune diseases ... providing a second notice of TNI BioTech,s annual meeting ... announcement, Noreen Griffin , founder and CEO of ... your participation in the Annual Meeting. On behalf of ...
(Date:8/18/2014)... August 18, 2014 China is ... for the clinical research industry. Clinicaltrial.gov statistics highlight ... to its aging population; a high increase in ... a densely populated pool of patients and a ... these positive points, China also presents challenges for ...
(Date:8/16/2014)... 16, 2014 Firms in the ... guidance and advisory services to businesses, government bodies ... Industry services are highly diverse as operators assist ... range from geological and geophysical consulting services to ... the past five years, the recovery of the ...
(Date:8/16/2014)... make atomic-force microscope probes 20 times more sensitive and ... of an individual virus. , The technique, developed by ... using laser beams to cool a nanowire probe to ... achieved after cooling is accurate enough for us to ... 100 billion times lighter than a mosquito," said Dr ...
Breaking Biology Technology:TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3Laser makes microscopes way cooler 2
... Feb. 4 Art,s Way Manufacturing, Inc. (Nasdaq: ... subsidiary, Art,s Way Scientific, Inc. - Buildings For ... - http://www.buildingsforscience.com/ The new site, reflective ... enhanced, clean and more user-friendly.Art,s Way Scientific ( ...
... (Nasdaq: KNDL ) announced today that it will ... closes on Tuesday, Feb. 24, 2009. The Company will host ... 25 at 8:30 a.m. Eastern Time. A question and answer ... participate in the telephone conference call, interested parties in the ...
... Patients Achieved an Objective Tumor Response by End of ... Inc. (Nasdaq: PPHM ) today reported that ... endpoint in the first stage of its ongoing Phase ... cancer (NSCLC). The open-label, Simon two-stage study is ...
Cached Biology Technology:Art's Way Manufacturing Announces Launch of New Web Site For Art's Way Scientific - Buildings For Science 2Art's Way Manufacturing Announces Launch of New Web Site For Art's Way Scientific - Buildings For Science 3Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 3Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 4
(Date:8/19/2014)... DIEGO, Calif. (August 19, 2014) Daylight was breaking ... MY Hanse Explorer. Between sips, about a dozen scientists ... and slip below the surface to collect water samples ... would tinker with the whirring gizmos and delicate machinery ... single goal: Be the first research group to bring ...
(Date:8/18/2014)... person,s gut may protect against or increase susceptibility to ... bacterial intestinal inflammation, according research published this week in ... American Society for Microbiology. The study also found that ... one,s gut bacteria composition. , "It has been known ... in the gut, can protect a person from colonization ...
(Date:8/18/2014)... UT Southwestern Medical Center have found a new way that ... known as long non-coding RNA. , The internal body clocks, ... functions, from waking and sleeping to body temperature and hunger. ... influenced by external cues such as light and temperature. , ... many organisms, what they do in the body, and how ...
Breaking Biology News(10 mins):Sequencing at sea 2Sequencing at sea 3What's in your gut? Certain bacteria may influence susceptibility to infection 2Researchers obtain key insights into how the internal body clock is tuned 2Researchers obtain key insights into how the internal body clock is tuned 3
... seeking to detect bioterrorism attacks, doctors diagnosing diseases ... a new ally in a Lawrence Livermore National ... as the Lawrence Livermore Microbial Detection Array (LLMDA), ... to detect within 24 hours any virus or ...
... prestigious Pierre Delmas Prize: An ESCEO-IOF/Servier Achievement Award was ... at the Claude Bernard University of Lyon, France. ... honour of the late Pierre D. Delmas, the world ... (IOF). The grant of 40,000 Euros, courtesy of Servier, ...
... A prescription drug already approved to treat genital warts and ... effectiveness of future vaccines for bacterial and viral diseases, such ... appear in ACS, Molecular Pharmaceutics , a bi-monthly journal. ... Research Center and UC-Berkeley note that vaccines prepared from weakened ...
Cached Biology News:New LLNL detection technology identifies bacteria, viruses, other organisms within 24 hours 2New LLNL detection technology identifies bacteria, viruses, other organisms within 24 hours 3Winner of Pierre Delmas Prize announced at World Congress on Osteoporosis 2010 2
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: